Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. (Q51284617)
Jump to navigation
Jump to search
scientific article published on 10 May 2016
Language | Label | Description | Also known as |
---|---|---|---|
English | Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. |
scientific article published on 10 May 2016 |
Statements
1 reference
Exenatide treatment decreases fasting fibroblast growth factor 21 levels in patients with newly diagnosed type 2 diabetes mellitus. (English)
1 reference
Y Hu
J Liu
H Zhang
Y Xu
10 May 2016
1 reference